Platzbecker, U., Crisa, E., Salazar, S., Cluzeau, T., Poloni, A., Arias, R. D. P., Comont, T., Grosicki, S., Giagounidis, A., Porta, M. D., Musto, P., Tormo, M., Brauer, D., Alfonso-Pierola, A., Paolini, S., Park, S., Weyn, A., Adès, L., Santini, V. (2025). Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS). Blood. https://doi.org/10.1182/blood-2025-5649